Renalytix Reports That The Centers For Medicare & Medicaid Services Has Published The Price For The Company's FDA-Authorized Kidneyintelx.Dkd Test On The Nationwide Clinical Laboratory Fee Schedule At $950: 8K
Portfolio Pulse from Benzinga Newsdesk
Renalytix has announced that the Centers for Medicare & Medicaid Services has published the price for the company's FDA-authorized KidneyIntelX.DKD test on the Nationwide Clinical Laboratory Fee Schedule at $950.
October 03, 2023 | 11:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The listing of Renalytix's KidneyIntelX.DKD test on the Nationwide Clinical Laboratory Fee Schedule at $950 by the Centers for Medicare & Medicaid Services could potentially increase the company's revenues.
The listing of Renalytix's KidneyIntelX.DKD test on the Nationwide Clinical Laboratory Fee Schedule at a significant price point of $950 indicates a potential increase in the company's revenues. This is because the listing could lead to wider adoption of the test by healthcare providers, thereby driving sales and revenue growth for Renalytix.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100